The role of sterile filtration in the biopharm industry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The role of sterile filtration in the biopharm industry


Pharmaceutical Technology Europe
Volume 23, Issue 1

Regulator concerns

The main concerns of regulators when it comes to sterile filtration depend on which regulator is consulted. Critical regulators very much stress the benefits of heat sterilisation versus sterilised filtration, a known fact acknowledged by everyone who has any scientific sense. Having said that, it would be an advantage if regulators, in contrast, acknowledged the fact that there are drug products that cannot be heat sterilised; in these instances, filtration is the best option.

In addition, when will regulators acknowledge the thousands of process validations performed by the industry with sterilising grade filters, the billions of litres filtered and the decades of experience? If similar scepticism were attached to flying, planes probably would only be used for short distance flights. The regulatory promotion of redundant filtration, pre-use integrity testing or the use of a tighter pore size should be left to the end user, as the decision to use either or all of the aforementioned is an economic decision after the filtration process has been properly validated.

The requested process validation (by all regulators) of sterilising grade filters is necessary and welcomed by filter manufacturers and end users alike. The stated tasks required during process validation are of help to any validation exercise and create a robust performance analysis of a sterilising grade filter. However, it would be good if regulators relied on their stated requirements when the industry performs the requested tasks and documents the outcome and reliability.

Optimising and improving current processes

The sterilising filtration of biopharmaceuticals generally means that a high value, low volume fluid is filtered. As such, oversized filtration systems, redundant filtration systems and, in single-use instances, tubing length, all contribute to excessive hold-up volume, i.e., valuable product losses. Therefore, the size and design of filter systems should not be neglected because these can impact the production process.

Again, unspecific adsorption, which is often neglected, should be tested very early in the drug development process to understand which filter membrane polymer is optimal for a particular fluid or application. Yields are very much influenced by unspecific adsorption and can vary greatly between membrane polymers. Total throughput — the volume that can be filtered through a specified filter device — also has an influence on yield. In some application, yield can drop dramatically when the filter starts blocking. This drop-off has to be determined in small-scale studies utilising flat disc filter composites — so-called indicator trials. When a filter needs to be scaled to production requirements, however, indicator trials are not sufficient and verification trials with small scale pleated devices should be used. The data of these trials are commonly reliable to scale the filter appropriately; again, the goal is not only to find a filter system that is able to process the entire volume, but also not to over-size. High flow rate is the desired parameter in some applications, but flow rate cannot be tested with 47 mm disc filters because the results would be meaningless. The flow dynamics and the filtration area within a 10 in. element requires testing in high flow applications. The interaction between the filter adapter and housing recess, as well as pipe work, the filter pleat behaviour under pressure and possible compression, can only be tested when the actual filter element is used.

In essence, a filter system can be compared to a well-defined recipe; too much as well as not enough can spoil it. Similarly, too much filtration area is as undesirable as too little.

Maik W. Jornitz is Senior Vice President, Marketing, at Sartorius-Stedim North America, Inc.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here